Rob Lambkin-Williams

Rob Lambkin-Williams

Auto-generated profile, based on publicly available information

Rob Lambkin-Williams

Vivo

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TWTom M Wilkinson
Tom M Wilkinson
CLChris K F Li
Chris K F Li
CCCecilia S C Chui
Cecilia S C Chui
AHArthur K Y Huang
Arthur K Y Huang
MPMolly Perkins
Molly Perkins
XXXiao-Ning Xu
Xiao-Ning Xu

1 September 2009 in Cell Host & Microbe
Verified
Journal Article
Closed access
AZAimee K. Zaas
Aimee K. Zaas
MCMinhua Chen
Minhua Chen
JVJay Varkey
Jay Varkey
TVTimothy Veldman
Timothy Veldman
AHAlfred O. Hero
Alfred O. Hero
GGGeoffrey S. Ginsburg
Geoffrey S. Ginsburg

26 April 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JDJohn DeVincenzo
John DeVincenzo
RLRobert Lambkin-Williams
Robert Lambkin-Williams
TWTom Wilkinson
Tom Wilkinson
JCJeffrey Cehelsky
Jeffrey Cehelsky
SNSara Nochur
Sara Nochur
AVAkshay Vaishnaw
Akshay Vaishnaw
RNA interference (RNAi) is a natural mechanism regulating protein expression that is mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human disease; however, clinical evidence for the effectiveness of this therapeutic approach is lacking. ALN-RSV01 is an siRNA directed against the mRNA of the respiratory syncytial virus (RSV) nucleocapsid (N) protein and has substantial antiviral activity in a murine model of RSV infection. We tested the antiviral activity of ALN-RSV01 in adults experimentally infected with wild-type RSV. Eighty-eight healthy subjects were enrolled into a randomized, double-blind, placebo-controlled trial. A nasal spray of ALN-RSV01 or saline placebo was administered daily for 2 days before and for 3 days after RSV inoculation. RSV was measured serially in nasal washes using several different viral assays. Intranasal ALN-RSV01 was well tolerated, exhibiting a safety profile similar to saline placebo. The proportion of culture-defined RSV infections was 71.4 and 44.2% in placebo and ALN-RSV01 recipients, respectively ( P = 0.009), representing a 38% decrease in the number of infected and a 95% increase in the number of uninfected subjects. The acquisition of infection over time was significantly lower in ALN-RSV01 recipients ( P = 0.007 and P = 0.03, viral culture and PCR, respectively). Multiple logistic regression analysis showed that the ALN-RSV01 antiviral effect was independent of other factors, including preexisting RSV antibody and intranasal proinflammatory cytokine concentrations. ALN-RSV01 has significant antiviral activity against human RSV infection, thus establishing a unique proof-of-concept for an RNAi therapeutic in humans and providing the basis for further evaluation in naturally infected children and adults.

21 August 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JDJohn P. DeVincenzo
John P. DeVincenzo
RWRichard J. Whitley
Richard J. Whitley
RMRichard L. Mackman
Richard L. Mackman
CSCecilia Scaglioni-Weinlich
Cecilia Scaglioni-Weinlich
LHLisa Harrison
Lisa Harrison
JCJason W. Chien
Jason W. Chien
Respiratory syncytial virus (RSV) is a common cause of infant hospitalizations and is increasingly recognized as a cause of considerable morbidity and mortality. No accepted antiviral treatment exists. We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry inhibitor, in healthy adults who received a clinical challenge strain of RSV intranasally. Participants were monitored for 12 days. At the time of a positive test for RSV infection or 5 days after inoculation, whichever occurred first, participants were randomly assigned to receive GS-5806 or placebo in one of seven sequential cohorts. Cohorts 1 to 4 received a first dose of 50 mg of GS-5806 and then 25 mg daily for the next 4 days, cohort 5 received a first dose of 50 mg and then 25 mg daily for the next 2 days, cohort 6 received one 100-mg dose, and cohort 7 received a first dose of 10 mg and then 5 mg daily for the next 4 days. Dose selection for cohorts 5, 6, and 7 occurred after an interim analysis of data for cohorts 1 to 4. The primary end point was the area under the curve (AUC) for the viral load, which was assessed after administration of the first dose through the 12th day after inoculation. Secondary end points were mucus weight and symptom scores. Among the 54 participants in cohorts 1 to 4 who were infected with RSV, active treatment was associated with a lower viral load (adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equivalents [PFUe] × hours per milliliter; P<0.001), lower total mucus weight (mean, 6.9 g vs. 15.1 g; P=0.03), and a lower AUC for the change from baseline in symptom scores (adjusted mean, −20.2 vs. 204.9 × hours; P=0.005). The results were similar in cohorts 5, 6, and 7. Adverse events, including low neutrophil counts and increased levels of alanine aminotransferase, were more common among participants receiving GS-5806. Treatment with GS-5806 reduced the viral load and the severity of clinical disease in a challenge study of healthy adults. (Funded by Gilead Sciences; ClinicalTrials.gov number, NCT01756482.)

15 November 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JDJohn P. DeVincenzo
John P. DeVincenzo
TWTom Wilkinson
Tom Wilkinson
AVAkshay Vaishnaw
Akshay Vaishnaw
JCJeff Cehelsky
Jeff Cehelsky
RMRachel Meyers
Rachel Meyers
RLRobert Lambkin-Williams
Robert Lambkin-Williams
Rationale: Respiratory syncytial virus (RSV) is the leading cause of childhood lower respiratory infection, yet viable therapies are lacking. Two major challenges have stalled antiviral development: ethical difficulties in performing pediatric proof-of-concept studies and the prevailing concept that the disease is immune-mediated rather than being driven by viral load. Objectives: The development of a human experimental wild-type RSV infection model to address these challenges. Methods: Healthy volunteers (n = 35), in five cohorts, received increasing quantities (3.0–5.4 log plaque-forming units/person) of wild-type RSV-A intranasally. Measurements and Main Results: Overall, 77% of volunteers consistently shed virus. Infection rate, viral loads, disease severity, and safety were similar between cohorts and were unrelated to quantity of RSV received. Symptoms began near the time of initial viral detection, peaked in severity near when viral load peaked, and subsided as viral loads (measured by real-time polymerase chain reaction) slowly declined. Viral loads correlated significantly with intranasal proinflammatory cytokine concentrations (IL-6 and IL-8). Increased viral load correlated consistently with increases in multiple different disease measurements (symptoms, physical examination, and amount of nasal mucus). Conclusions: Viral load appears to drive disease manifestations in humans with RSV infection. The observed parallel viral and disease kinetics support a potential clinical benefit of RSV antivirals. This reproducible model facilitates the development of future RSV therapeutics.

1 August 2002 in Antiviral Research
Verified
Journal Article
Closed access
JIJ.A.L. Ives
J.A.L. Ives
JCJ.A. Carr
J.A. Carr
DMD.B. Mendel
D.B. Mendel
CTC.Y. Tai
C.Y. Tai
RLR. Lambkin
R. Lambkin
NRN.A. Roberts
N.A. Roberts